The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
David S. Baldwin - One of the best experts on this subject based on the ideXlab platform.
-
Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder
Translational Medicine in CNS Drug Development, 2019Co-Authors: David S. Baldwin, Ayman Abou-aishaAbstract:Abstract Numerous pharmacological and psychological approaches are efficacious in patients with generalized anxiety disorder (GAD) and social anxiety disorder (SAD), though some patients do not respond to treatment and others relapse despite continuing with interventions that were initially beneficial. Other patients respond but stop treatment because of unwanted effects including sexual dysfunction, emotional blunting, and weight gain. There is much need for novel interventions with greater overall effectiveness and enhanced acceptability when compared with current treatments or with particular effectiveness in specific patient groups. “Experimental Medicine” studies conducted in healthy subjects provide a “proof-of-concept” approach for determining whether to progress to pivotal efficacy studies, thereby potentially reducing delays in translating innovations into clinical practice. Examples of such studies include inhalation of air “enriched” with 7.5% carbon dioxide, which mirrors the subjective, autonomic, and cognitive features of GAD, and administration of testosterone or oxytocin, which respectively target the social avoidance and emotion processing biases of SAD.
-
Experimental Medicine approaches to drug development in anxiety disorders
2018Co-Authors: David S. Baldwin, Abou-aisha AymanAbstract:Numerous pharmacological and psychological approaches are efficacious in patients with generalized anxiety disorder (GAD) and social anxiety disorder (SAD), though some patients do not respond to treatment and others relapse despite continuing with interventions that were initially beneficial. Other patients respond but stop treatment because of unwanted effects including sexual dysfunction, emotional blunting and weight gain. There is much need for novel interventions with greater overall effectiveness and enhanced acceptability when compared to current treatments, or with particular effectiveness in specific patient groups. ‘Experimental Medicine’ studies conducted in healthy subjects provide a ‘proof-of-concept’ approach for determining whether to progress to pivotal efficacy studies, thereby potentially reducing delays in translating innovations into clinical practice. Examples of such studies include inhalation of air ‘enriched’ with 7.5% carbon dioxide, which mirrors the subjective, autonomic and cognitive features of GAD, and administration of testosterone or oxytocin, which respectively target the social avoidance and emotion processing biases of SAD.
-
pharmacotherapy in generalized anxiety disorder novel Experimental Medicine models and emerging drug targets
CNS Drugs, 2017Co-Authors: David S. Baldwin, Robert Gordon, Nathan T. M. Huneke, Matthew GarnerAbstract:Many pharmacological and psychological approaches have been found efficacious in patients with generalized anxiety disorder (GAD), but many treatment-seeking patients will not respond and others will relapse despite continuing with interventions that initially had beneficial effects. Other patients will respond but then stop treatment early because of untoward effects such as sexual dysfunction, drowsiness, and weight gain. There is much scope for the development of novel approaches that could have greater overall effectiveness or acceptability than currently available interventions or that have particular effectiveness in specific clinical subgroups. ‘Experimental Medicine’ studies in healthy volunteers model disease states and represent a proof-of-concept approach for the development of novel therapeutic interventions: they determine whether to proceed to pivotal efficacy studies and so can reduce delays in translating innovations into clinical practice. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic, and cognitive features of GAD. The anxiety response during CO2 challenge probably involves both central noradrenergic neurotransmission and effects on acid-base sensitive receptors and so may stimulate development of novel agents targeted at central chemosensors. Increasing awareness of the potential role of altered cytokine balance in anxiety and the interplay of cytokines with monoaminergic mechanisms may also encourage the investigation of novel agents with modulating effects on immunological profiles. Although seemingly disparate, these two approaches to treatment development may pivot on a shared mechanism in exerting anxiolytic-like effects through pharmacological effects on acid-sensing ion channels.
-
GAD: Experimental Medicine models, emerging targets: Pharmacotherapy in generalized anxiety disorder: novel Experimental Medicine models and emerging drug targets
2017Co-Authors: David S. Baldwin, Robert Gordon, Nathan T. M. Huneke, Matthew GarnerAbstract:Many pharmacological and psychological approaches have been found efficacious in patients with generalized anxiety disorder (GAD), but many treatment-seeking patients will not respond and others will relapse despite continuing with interventions which initially had beneficial effects. Other patients will respond, but then stop treatment early because of untoward effects such as sexual dysfunction, drowsiness and weight gain. There is much scope to develop novel approaches, which could have greater overall effectiveness or acceptability than currently available interventions, or which have particular effectiveness in specific clinical sub-groups. ‘Experimental Medicine’ studies in healthy volunteers model disease states and represent a ‘proof-of-concept’ approach for the development of novel therapeutic interventions: they determine whether to proceed to pivotal efficacy studies, and so can reduce delays in translating innovations into clinical practice. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic and cognitive features of GAD. The anxiety response during CO2 challenge probably involves both central noradrenergic neurotransmission and effects on acid-base sensitive receptors, and so may stimulate development of novel agents targeted at central chemosensors. Increasing awareness of the potential role of altered cytokine balance in anxiety and the interplay of cytokines with monoaminergic mechanisms may also encourage the investigation of novel agents with modulating effects on immunological profiles. Although seemingly disparate, these two approaches to treatment development may pivot on a shared mechanism in exerting anxiolytic-like effects through pharmacological effects on acid-sensing ion channels Key Points Generalized anxiety disorder (GAD) is a common and impairing condition for which currently available pharmacological and psychological treatments are not ideal, having sub-optimal efficacy and acceptability problems in both short-term and long-term treatment. ‘Experimental Medicine’ studies in healthy volunteers provide useful ‘proof-of-concept’ approaches in the development of novel pharmacological and psyschological interventions: two promising avenues include the development of novel agents targeted at central chemosensors, or at modulating immunological responses. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic and cognitive features of GAD.
Paul M Matthews - One of the best experts on this subject based on the ideXlab platform.
-
non invasive imaging in Experimental Medicine for drug development
Current Opinion in Pharmacology, 2011Co-Authors: Paul M Matthews, Ilan Rabiner, Roger N GunnAbstract:Clinical imaging offers a range of methods for the support of drug development that are able to address major questions related to target validation and molecule biodistribution, target interactions and pharmacodynamics. Here we review recent innovative applications of positron emission tomography (PET) and magnetic resonance imaging (MRI). New approaches to human target validation exploring MRI or PET biomarker changes related to allelic variation at candidate target loci can contribute to human target validation. PET molecular imaging can define molecule biodistribution directly and, if an appropriate, target-specific radioligand is available, be employed in small Experimental Medicine studies to provide plasma pharmacokinetic–target occupancy data to guide dose selection. An enlarging range of imaging biomarkers for pharmacodynamic studies is enabling imaging Experimental Medicine studies to assess the potential efficacy of new therapeutic molecules. Integration of these approaches promises improvements in therapeutic molecule differentiation and may contribute in ways that would improve the value proposition for use of a new drug through patient stratification.
-
Noninvasive brain imaging for Experimental Medicine in drug discovery.
Expert Opinion on Drug Discovery, 2006Co-Authors: Paul M Matthews, Richard Geoffrey WiseAbstract:There is a widely shared perception that it is becoming increasingly urgent to find reliable measures related to therapeutic efficacy for use as early as possible in drug development. The inadequate understanding of diseases, limitations of animal models and difficulties in using their responses to anticipate drug effects in humans highlights the need to develop tools in Experimental Medicine to characterise human disease directly. Noninvasive imaging, particularly positron emission tomography and magnetic resonance imaging, provide a powerful range of methods for serial observation of drug distribution and interactions, and for assessing potential therapeutic mechanisms. Using imaging technology to establish biological proof-of-principle and as a pharmacodynamic marker for dose ranging would contribute greatly to the speed and efficiency of early decision making in new drug development. Imaging methods offer the ultimate promise for the development of clinically predictive surrogate markers of disease re...
-
Noninvasive Brain Imaging for Experimental Medicine in Drug Discovery and Development Promise and Pitfalls
International Journal of Pharmaceutical Medicine, 2006Co-Authors: Brandon Whitcher, Paul M MatthewsAbstract:There is currently increased focus on Experimental Medicine in drug development. Imaging methods potentially provide highly cost-effective, general approaches for the noninvasive characterisation of disease and pharmacokinetics, pharmacodynamics and drug effects directly in humans in ways that can enable this. The two methods most widely employed now are positron emission tomography (PET) and magnetic resonance imaging (MRI). PET allows the distribution of radiolabelled molecules to be mapped, enabling studies of molecule distribution and tissue metabolism. MRI was initially used primarily to define tissue structure, but a more recent range of functional MRI techniques promise the potential to define pharmacokinetic data over biologically meaningful timescales. With an understanding of the relationship between imaging biomarker changes and clinical outcomes, imaging can be used as a surrogate marker of response even for the later stages of drug development.
Matthew Garner - One of the best experts on this subject based on the ideXlab platform.
-
pharmacotherapy in generalized anxiety disorder novel Experimental Medicine models and emerging drug targets
CNS Drugs, 2017Co-Authors: David S. Baldwin, Robert Gordon, Nathan T. M. Huneke, Matthew GarnerAbstract:Many pharmacological and psychological approaches have been found efficacious in patients with generalized anxiety disorder (GAD), but many treatment-seeking patients will not respond and others will relapse despite continuing with interventions that initially had beneficial effects. Other patients will respond but then stop treatment early because of untoward effects such as sexual dysfunction, drowsiness, and weight gain. There is much scope for the development of novel approaches that could have greater overall effectiveness or acceptability than currently available interventions or that have particular effectiveness in specific clinical subgroups. ‘Experimental Medicine’ studies in healthy volunteers model disease states and represent a proof-of-concept approach for the development of novel therapeutic interventions: they determine whether to proceed to pivotal efficacy studies and so can reduce delays in translating innovations into clinical practice. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic, and cognitive features of GAD. The anxiety response during CO2 challenge probably involves both central noradrenergic neurotransmission and effects on acid-base sensitive receptors and so may stimulate development of novel agents targeted at central chemosensors. Increasing awareness of the potential role of altered cytokine balance in anxiety and the interplay of cytokines with monoaminergic mechanisms may also encourage the investigation of novel agents with modulating effects on immunological profiles. Although seemingly disparate, these two approaches to treatment development may pivot on a shared mechanism in exerting anxiolytic-like effects through pharmacological effects on acid-sensing ion channels.
-
GAD: Experimental Medicine models, emerging targets: Pharmacotherapy in generalized anxiety disorder: novel Experimental Medicine models and emerging drug targets
2017Co-Authors: David S. Baldwin, Robert Gordon, Nathan T. M. Huneke, Matthew GarnerAbstract:Many pharmacological and psychological approaches have been found efficacious in patients with generalized anxiety disorder (GAD), but many treatment-seeking patients will not respond and others will relapse despite continuing with interventions which initially had beneficial effects. Other patients will respond, but then stop treatment early because of untoward effects such as sexual dysfunction, drowsiness and weight gain. There is much scope to develop novel approaches, which could have greater overall effectiveness or acceptability than currently available interventions, or which have particular effectiveness in specific clinical sub-groups. ‘Experimental Medicine’ studies in healthy volunteers model disease states and represent a ‘proof-of-concept’ approach for the development of novel therapeutic interventions: they determine whether to proceed to pivotal efficacy studies, and so can reduce delays in translating innovations into clinical practice. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic and cognitive features of GAD. The anxiety response during CO2 challenge probably involves both central noradrenergic neurotransmission and effects on acid-base sensitive receptors, and so may stimulate development of novel agents targeted at central chemosensors. Increasing awareness of the potential role of altered cytokine balance in anxiety and the interplay of cytokines with monoaminergic mechanisms may also encourage the investigation of novel agents with modulating effects on immunological profiles. Although seemingly disparate, these two approaches to treatment development may pivot on a shared mechanism in exerting anxiolytic-like effects through pharmacological effects on acid-sensing ion channels Key Points Generalized anxiety disorder (GAD) is a common and impairing condition for which currently available pharmacological and psychological treatments are not ideal, having sub-optimal efficacy and acceptability problems in both short-term and long-term treatment. ‘Experimental Medicine’ studies in healthy volunteers provide useful ‘proof-of-concept’ approaches in the development of novel pharmacological and psyschological interventions: two promising avenues include the development of novel agents targeted at central chemosensors, or at modulating immunological responses. Investigations in healthy volunteers challenged with the inhalation of air ‘enriched’ with 7.5% carbon dioxide (CO2) indicate this technique provides a validated and robust Experimental Medicine model, mirroring the subjective, autonomic and cognitive features of GAD.
Catherine J Harmer - One of the best experts on this subject based on the ideXlab platform.
-
tianeptine in an Experimental Medicine model of antidepressant action
Journal of Psychopharmacology, 2015Co-Authors: Charlotte M Cooper, Daniel A Whiting, P J Cowen, Catherine J HarmerAbstract:Changes in emotional processing have been shown following acute administration of a range of monoaminergic antidepressants, and may represent an important common neuropsychological mechanism underpinning their therapeutic effects. Tianeptine is an agent that challenges the traditional monoaminergic hypothesis of antidepressant action, though its exact mode of action remains controversial. Healthy volunteers were randomised to receive a single dose of tianeptine (12.5 mg) or placebo, and subsequently completed a battery of tasks measuring emotional processing, including facial expression recognition, emotional memory and attentional vigilance, as well as working and verbal memory. Tianeptine-treated subjects were less accurate at identifying facial expressions, though this was not valence specific. The tianeptine group also showed reduced positive affective memory and reduced attentional vigilance to positive stimuli. There were no effects on emotional categorization or non-emotional cognition. The negativ...
-
using an Experimental Medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety
Neuropsychopharmacology, 2011Co-Authors: Michael Browning, Guy M. Goodwin, Maud Grol, Verena Ly, Emily A Holmes, Catherine J HarmerAbstract:Using an Experimental Medicine Model to Explore Combination Effects of Pharmacological and Cognitive Interventions for Depression and Anxiety
D. Rassier - One of the best experts on this subject based on the ideXlab platform.
-
Muscle Biophysics. From Molecules To Cells (Advances In Experimental Medicine And Biology, Vol. 682)
2010Co-Authors: D. RassierAbstract:Muscle Biophysics. From Molecules To Cells (Advances In Experimental Medicine And Biology, Vol. 682) - Libros de Medicina - Biofisica - 258,96
-
Comprar Muscle Biophysics. From Molecules To Cells (Advances In Experimental Medicine And Biology, Vol. 682) | D. Rassier | 9781441963659 | Springer
2010Co-Authors: D. RassierAbstract:Tienda online donde Comprar Muscle Biophysics. From Molecules To Cells (Advances In Experimental Medicine And Biology, Vol. 682) al precio 271,91 € de D. Rassier, tienda de Libros de Medicina, Libros de Biologia - Biofisica
